The FDA has granted orphan drug designation to Cure Rare Disease’s CRD-002, an antisense oligonucleotide therapeutic for the treatment of spinocerebellar ataxia (SCA), including spinocerebellar ataxia ...

A new mechanism that worsens the symptoms of cerebellar ataxia, a rare degenerative cerebellar disease, has been identified.

Ataxia affects the nervous system, disrupting muscle control, coordination, and balance. It can be hereditary, acquired, or sporadic, with each type requiring different diagnostic methods and care ...

A team has conducted a trial on the efficacy and safety of L-arginine in treating spinocerebellar ataxia type 6 (SCA6). The findings are published in the journal eClinicalMedicine, and the team was ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial will evaluate VO659, an antisense ...

Worldwide, only a handful of patients are known to suffer from episodic ataxia type 6, a neurological disease that causes transient loss of muscle control. The cause lies in a mutation that changes a ...

Ataxia is more than just clumsiness—it’s a neurological condition that affects coordination, balance, speech, and even vision ...

SALT LAKE CITY - Scientists report a significant step toward combatting two degenerative brain diseases that chip away at an individual's ability to move, and think. A targeted therapy developed by ...

Stefan Pulst, a neurologist at the University of Utah, sees hundreds of patients each year with puzzling brain diseases. But 15 years ago, he met a patient whom he thought could be the key to solving ...